The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study
Abstract
Purpose: On the basis of reported activity of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) or topotecan plus cisplatin in advanced cervix cancer, we undertook a randomized trial comparing these combinations versus cisplatin alone, to determine whether survival is improved with either combination compared with cisplatin alone, and to compare toxicities and quality of life (QOL) among the regimens. Patients and Methods: Eligible patients were randomly allocated to receive cisplatin 50 mg/m 2 every 3 weeks (CPT); cisplatin 50 mg/m 2 day 1 plus topotecan 0.75 mg/m 2 days 1 to 3 every 3 weeks (CT); or methotrexate 30 mg/m 2 days 1, 15, and 22, vinblastine 3 mg/m 2 days 2, 15, and 22, doxorubicin 30 mg/m 2 day 2, and cisplatin 70 mg/m 2 day 2 every 4 weeks (MVAC). Survival was the primary end point; response rate and progression-free survival (PFS) were secondary end points. QOL data are reported separately. Results: The MVAC arm was closed by the Data Safety Monitoring Board after four treatment-related deaths occurred among 63 patients, and is not included in this analysis. Two hundred ninety-four patients enrolled onto the remaining regimens: 146 to CPT and 147 to CT. Grade 3 to 4 hematologic toxicity was more common with CT. Patients receiving CT had statistically superior outcomes to those receiving CPT, with median overall survival of 9.4 and 6.5 months (P = .017), median PFS of 4.6 and 2.9 months (P = .014), and response rates of 27% and 13%, respectively. Conclusion: This is the first randomized phase III trial to demonstrate a survival advantage for combination chemotherapy over cisplatin alone in advanced cervix cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Use of Ranks in One-Criterion Variance Analysis
Kruskal, W. H., & Wallis, W. A. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483441 · Cited by 13,912
Sample-Size Formula for the Proportional-Hazards Regression Model
Schoenfeld, D. A. (1983) · Biometrics · doi:10.2307/2531021 · Cited by 1,096
Moore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.170 · Cited by 635
Self-citationBonomi, P., Blessing, J. A., Stehman, F. B., DiSaia, P. J., Walton, L., & Major, F. J. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.8.1079 · Cited by 402
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
McGuire, W. P., Blessing, J. A., Moore, D. H., Lentz, S. S., & Photopulos, G. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.792 · Cited by 217
Muderspach, L. I., Blessing, J. A., Levenback, C., & Moore, J. L. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6024 · Cited by 118
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems
Romanelli, S., Perego, P., Pratesi, G., et al. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050755 · Cited by 115
Thigpen, T., Shingleton, H. M., Homesley, H. D., Lagasse, L. D., & Blessing, J. A. (1979) · PubMed · Cited by 74
Cited by
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Self-citationCervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Monk, B. J., Sill, M. W., McMeekin, D. S., Cohn, D. E., Ramondetta, L. M., Boardman, C. H., Benda, J., & Cella, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8909 · Cited by 693
Self-citationBermudez, A., Bhatla, N., & Leung, E. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2015.06.004 · Cited by 657
Metadata
- Authors
- Long, H. J., Bundy, B. N., Grendys, E. C., Benda, J. A., McMeekin, D. S., Sorosky, J., Miller, D. S., Eaton, L. A., & Fiorica, J. V.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-07-20
- Volume
- 23
- Issue
- 21
- Pages
- 4626-4633
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171725862
- Cited by
- 556
- References
- 11
- FWCI
- 33.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.